Vol. 10 No. 2 (2025): Educational Yield Insights & Breakthroughs (EYIB)
Articles

METOBOLIK SINDROMDA XOLESTERIN METABOLIZMINING O‘ZGARISHI

pdf
  • Surayyo Axmedova,
  • Sarvinoz Xamidullayeva,
  • Nargiz Qutbiyeva
Surayyo Axmedova
Toshkent davlat tibbiyot universiteti
Sarvinoz Xamidullayeva
Toshkent davlat tibbiyot universiteti
Nargiz Qutbiyeva
Toshkent davlat tibbiyot universiteti

Published 2025-12-07

Keywords

  • metabolik sindrom, dislipidemiya, xolesterin metabolizmi, LDL, HDL, triglitserid, atherogenez, small dense LDL.

Abstract

Ushbu maqola Metabolik sindrom (MS) holatida xolesterin va lipid metabolizmining o‘zgarishlari, ya’ni dislipidemiya shakllanishi, lipoprotein fraksiyalarining qayta taqsimlanishi (triglitseridlar, HDL, LDL, ayniqsa kichik zichlikli LDL), shuningdek, bu o‘zgarishlarning aterogenez va yurak-qon tomir kasalliklari (YQTK) xavfi bilan bogʻliqligi hamda patofizyologik mexanizmlar — yallig‘lanish, oksidlov, reverse xolesterin transporti buzilishi orqali qanday namoyon bo‘lishini tahlil qiladi. Mavjud adabiyotlar tizimli sharhi va statistik ma’lumotlar asosida sintez qilindi. Maqola klinik va profilaktik tavsiyalar ham beradi.

pdf

References

  1. Aggarwal DJ, Kathariya MG, Verma DPK. LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker. Indian Heart J. 2021 Sep-Oct;73(5):544-548. doi: 10.1016/j.ihj.2021.07.013. Epub 2021 Jul 31. PMID: 34627566; PMCID: PMC8514398.
  2. Alcover, S., Ramos-Regalado, L., Girón, G., Muñoz-García, N., & Vilahur, G. (2025). HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome. Antioxidants, 14(4), 434. https://doi.org/10.3390/antiox14040434
  3. Al-Zakwani, I., Al Mahmeed, W., Shehab, A., Arafah, M., Al-Hinai, A. T., Al Tamimi, O., Al Awadhi, M., Al Herz, S., Al Anazi, F., Al Nemer, K., … & Al-Rasadi, K. (2016). Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study. Diabetology & Metabolic Syndrome, 8, Article 49. https://doi.org/10.1186/s13098-016-0160-6
  4. Ascaso, J. F., Millán, J., Hernández-Mijares, A., Blasco, M., Brea, Á., Díaz, Á., … SEA Atherogenic Dyslipidaemia Working Group. (2020). Atherogenic Dyslipidaemia 2019: Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society. Clínica e Investigación en Arteriosclerosis (English Edition), 32(3), 120–125. https://doi.org/10.1016/j.artere.2020.05.002
  5. Bekbossynova, M., Saliev, T., Ivanova-Razumova, T., Andossova, S., Kali, A., & Myrzakhmetova, G. (2025). Small dense LDL: An underestimated driver of atherosclerosis (Review). Molecular Medicine Reports, 32, 328. https://doi.org/10.3892/mmr.2025.13693
  6. Blaton, V. H., Korita, I., & Bulo, A. (2008). How is metabolic syndrome related to dyslipidemia? Biochemia Medica, 18, 14–24. https://doi.org/10.11613/BM.2008.003
  7. Eckel, R. Treating dyslipidemia of the metabolic syndrome: where's the evidence?. Nat Rev Endocrinol 3, 437 (2007). https://doi.org/10.1038/ncpendmet0514
  8. Fan J, Liu Y, Yin S, Chen N, Bai X, Ke Q, Shen J, Xia M. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation. Nutr Metab (Lond). 2019 Jan 21;16:7. doi: 10.1186/s12986-019-0334-y. PMID: 30679939; PMCID: PMC6341753.
  9. Grundy, S. M. (1997). Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation, 95(1), 1–4. https://doi.org/10.1161/01.CIR.95.1.1
  10. Hirayama, S., & Miida, T. (2012). Small dense LDL: An emerging risk factor for cardiovascular disease. Atherosclerosis, 224 (2), 309–323. https://doi.org/10.1016/j.atherosclerosis.2012.05.046
  11. Lorenzatti, A. J., & Toth, P. P. (2020). New perspectives on atherogenic dyslipidaemia and cardiovascular disease. European Cardiology Review, 15, e04. https://doi.org/10.15420/ecr.2019.06
  12. Ma, Y., Zhai, X., Mu, D., Gao, Y., Li, Y., Qiu, L., Li, K. & Cheng, X. (2025). Superior prognostic value of estimated small dense LDL cholesterol for cardiovascular risk assessment: evidence from international cohort studies. Lipids in Health and Disease, 24, Article 321. https://doi.org/10.1186/s12944-025-02717-0
  13. Manjunath CN, Rawal JR, Irani PM, Madhu K. Atherogenic dyslipidemia. Indian J Endocrinol Metab. 2013 Nov;17(6):969-76. doi: 10.4103/2230-8210.122600. PMID: 24381869; PMCID: PMC3872713.
  14. Martin, M., & his colleagues. (2024). Impaired reverse cholesterol transport is associated with changes in fatty acid profile in children and adolescents with abdominal obesity. The Journal of Nutrition. Advance online publication. https://doi.org/10.1093/jn/nxad72603
  15. Ortiz-Pérez, M. A., Tello-García, M. P., & González-Pulido, J. (2018). Evaluation of non-HDL cholesterol as predictor of cardiovascular risk: a comparative study with LDL-C and ApoB. Revista Clínica e Investigación en Arteriosclerosis (English Edition), 415, Article S2529912318000165. https://doi.org/10.1016/j.arteri.2018.05.004
  16. Ramjee, V, Sperling, L, Jacobson, T. Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification: Do the Math. JACC. 2011 Jul, 58 (5) 457–463.https://doi.org/10.1016/j.jacc.2011.05.009
  17. Rizzo, M., & Berneis, K. (2007). Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes/Metabolism Research and Reviews, 23(1), 14-20. https://doi.org/10.1002/dmrr.694
  18. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012 Feb;14(1):1-10. doi: 10.1007/s11883-011-0219-7. PMID: 22102062; PMCID: PMC3697085.
  19. Sehayek, D., & Cole, J. A. (2025). ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk: a discordance analysis. Journal of Clinical Lipidology. Advance online publication. https://doi.org/10.1016/j.jacl.2025.000XXX
  20. Stoicescu, C., Vacarescu, C., & Cozma, D. (2025). HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications. Journal of Clinical Medicine, 14(14), 4945. https://doi.org/10.3390/jcm14144945
  21. von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023). High-density lipoprotein revisited: biological functions and clinical relevance. European Heart Journal, 44(16), 1394–1407. https://doi.org/10.1093/eurheartj/ehac605
  22. Zhu X, Chen Y, Zhu M, Hu J. The Relationship Between Small Dense Low-Density Lipoprotein Cholesterol and Metabolic Syndrome. Diabetes Metab Syndr Obes. 2024 Mar 30;17:1523-1532. doi: 10.2147/DMSO.S450783. PMID: 38576450; PMCID: PMC10992673.
  23. Zila-Velasque, J.P., Grados-Espinoza, P., Challapa-Mamani, M.R. et al. Prevalence of metabolic syndrome and its components according to altitude levels: a systematic review and meta-analysis. Sci Rep 14, 27581 (2024). https://doi.org/10.1038/s41598-024-77928-z